Literature DB >> 33504502

Covid-19 controversies: the tocilizumab chapter.

Erin K McCreary1, Nuala J Meyer2.   

Abstract

Entities:  

Year:  2021        PMID： 33504502     DOI： 10.1136/bmj.n244

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.

Authors:  Émilien Schultz; Léo Mignot; Jeremy K Ward; Daniela Boaventura Bomfim; Christian Chabannon; Julien Mancini
Journal:  Therapie       Date:  2022-05-07       Impact factor: 3.367

2.  Interleukin-6 blocking agents for treating COVID-19: a living systematic review.

Authors:  Lina Ghosn; Anna Chaimani; Theodoros Evrenoglou; Mauricia Davidson; Carolina Graña; Christine Schmucker; Claudia Bollig; Nicholas Henschke; Yanina Sguassero; Camilla Hansen Nejstgaard; Sonia Menon; Thu Van Nguyen; Gabriel Ferrand; Philipp Kapp; Carolina Riveros; Camila Ávila; Declan Devane; Joerg J Meerpohl; Gabriel Rada; Asbjørn Hróbjartsson; Giacomo Grasselli; David Tovey; Philippe Ravaud; Isabelle Boutron
Journal:  Cochrane Database Syst Rev       Date:  2021-03-18

3.  Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.

Authors:  Cori Campbell; Monique I Andersson; M Azim Ansari; Olivia Moswela; Siraj A Misbah; Paul Klenerman; Philippa C Matthews
Journal:  Front Med (Lausanne)       Date:  2021-08-20

4.  Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.

Authors:  Princy N Kumar; Jules Hernández-Sánchez; Sandra Nagel; Yuning Feng; Fang Cai; Joseph Rabin; Caryn G Morse; Nandita R Nadig; Obaid Ashraf; Deepa B Gotur; Grace A McComsey; Khalid Gafoor; Patrick Perin; Sarah C Thornton; William Stubbings; Celia J F Lin; Larry Tsai
Journal:  Open Forum Infect Dis       Date:  2021-12-04       Impact factor: 3.835

Review 5.  Signals were broadly positive for months, but never definitive: the tocilizumab story.

Authors:  Alessandro Cozzi-Lepri; Colette Smith; Cristina Mussini
Journal:  Clin Microbiol Infect       Date:  2021-11-09       Impact factor: 8.067

6.  A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.

Authors:  Amir Behnam Kharazmi; Omid Moradi; Mehrdad Haghighi; Mehran Kouchek; Alireza Manafi-Rasi; Masoomeh Raoufi; Simin Dokht Shoaei; Fahimeh Hadavand; Mahmood Nabavi; Mir Mohammad Miri; Sara Salarian; Seyedpouzhia Shojaei; Shayesteh Khalili; Mohammad Sistanizad; Setayesh Sadeghi; Amirhossein Karagah; Saemeh Asgari; Morteza Jaffaraghaei; Shahram Araghi
Journal:  Immun Inflamm Dis       Date:  2021-11-11

7.  Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.

Authors:  Austė Kanapeckaitė; Asta Mažeikienė; Liesbet Geris; Neringa Burokienė; Graeme S Cottrell; Darius Widera
Journal:  Biophys Chem       Date:  2022-09-11       Impact factor: 3.628

8.  Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.

Authors:  Shivanthan Shanthikumar; Sarath C Ranganathan; Richard Saffery; Melanie R Neeland
Journal:  Front Immunol       Date:  2021-10-15       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.